Evaluating liquid biopsy for cancer diagnosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of liquid biopsy, specifically through circulating tumor DNA analysis, in identifying molecular abnormalities in patients with advanced-stage malignant solid tumors. The study compares the results of liquid biopsies to traditional solid biopsies, which are considered the gold standard. Participants will provide blood samples for analysis, and the findings will be discussed in a multidisciplinary molecular biology meeting to guide patient management.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Over 18 years old.
* Advanced-stage malignant solid tumor managed in a non-curative context.
* Patient eligible for Multidisciplinary molecular biology meeting with available archived tumor material (frozen or FFPE block, less than 5 years old) or a biopsiable tumor lesion.
* Patient able to read, write, and understand the French language.
* Patient has read the information sheet and signed the informed consent.
* Patient has social security coverage.

Exclusion Criteria:

* Previous or concurrent cancer diagnosed or treated within the last 5 years, except for in situ carcinoma of the cervix, basal cell or squamous cell carcinoma of the skin, and adequately treated in situ carcinoma of the bladder.
* Severe or uncontrolled systemic disease.
* Any condition which, in the investigator's judgment (geographical, social, or psychological factors, etc.), makes the patient unable to comply with study follow-up and procedures.
* Patient considered a vulnerable person; vulnerable persons are defined in Articles L1121-5 to L1121-8:

  * Pregnant women, women in labor, and breastfeeding mothers,
  * Persons deprived of liberty by judicial or administrative decision, individuals hospitalized without consent under Articles L. 3212-1 and L. 3213-1 who do not fall under the provisions of Article L. 1121-8,
  * Persons admitted to a healthcare or social institution for reasons other than research,
  * Adults unable to give their consent.

Where it's running

• Centre Antoine Lacassagne
  Nice, France Recruiting

Study contacts

• Study coordinator: Study coordinator
• Email: DRCI-Promotion@nice.unicancer.fr
• Phone: +33 04 92 03 14 76

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Calderasib (MK-1084) with or without cetuximab for advanced KRAS G12C solid tumors

  This study will test whether calderasib (MK-1084), alone or combined with cetuximab, can shrink advanced solid tumors in people whose cancers have the KRAS G12C mutation.

  Recruiting at 71 sites Phase 2 Merck Sharp & Dohme LLC · Baltimore, Maryland and 71 other locations · NCT07209111

• Creating tumor models to test new cancer treatments

  This study is trying to see how well new cancer treatments work on tumor samples from patients with specific mutations.

  Recruiting Centre Antoine Lacassagne · Nice · NCT06782451

• Observing cancer outcomes in patients receiving integrative oncology care

  This study is testing how well combining naturopathic medicine with regular cancer treatments helps early-stage and advanced-stage cancer patients live longer and stay healthy.

  Recruiting Advanced Integrative Medical Science Institute · Seattle, Washington · NCT04495790

• Using a virus therapy to treat recurrent cerebellar brain tumors in children

  This study is testing a new virus treatment for children with recurring brain tumors to see if it can help them get better when combined with a low dose of radiation.

  Recruiting at 3 sites Phase 1 M.D. Anderson Cancer Center · Birmingham, Alabama and 2 other locations · NCT03911388

• Exploring the link between body weight and quality of life in cancer patients

  This study is trying to see how body weight affects the quality of life for adults with solid tumors, like breast or lung cancer.

  Recruiting University of Rome Tor Vergata · Rome · NCT03873064

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.